3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
5
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Radiosurgery
51
Magnetic Resonance Spectroscopy
34
Temozolomide
28
pembrolizumab
24
Bevacizumab
24
Radiotherapy
20
Nivolumab
20
Specimen Handling
14
Ipilimumab
13
Cyclophosphamide
13
Mental Status and Dementia Tests
12
Carboplatin
12
abemaciclib
10
Radiation
10
Blood Specimen Collection
9
trastuzumab deruxtecan
8
Proton Therapy
7
Pemetrexed
7
Memantine
7
fluciclovine F-18
6
binimetinib
6
Paclitaxel
6
Etoposide
6
Cisplatin
6
Capecitabine
6
encorafenib
5
Trastuzumab
5
Surveys and Questionnaires
5
Surgical Procedures, Operative
5
Lomustine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
RAD1901
×
1 year
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled